We observed a 40-year-old woman with necrobiotic xanthogranuloma from the inception of indurated eyelid and periorbital infiltrates and concurrent stage I multiple myeloma to resolution of infiltrates in skin and bone marrow after pulsed high-dose oral dexamethasone therapy. Ultrastructural studies revealed lipid vacuoles in epidermal keratinocytes, in dermal histiocytic macrophages, and in vascular and lymphatic endothelial cells. The presence of lipid vacuoles in epidermal keratinocytes has not been reported previously in xanthogranuloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0190-9622(91)70208-j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of ulcerated nodules in association with a monoclonal gammopathy.
JAAD Case Rep
December 2024
Department of Dermatology, Kings College Hospital, London, UK.
Foamy Cell Angiosarcoma Resembling a Xanthomatous Histiocytic Infiltrate Without Evidence of Vascular Malignancy.
J Cutan Pathol
December 2024
Department of Medicine, Division of Dermatology, St. Louis School of Medicine, Washington University, St. Louis, Missouri, USA.
Angiosarcoma is a rare and aggressive malignancy of endothelial cells with multiple subtypes. Foamy cell angiosarcoma is a rare variant in which endothelial cells demonstrate "foamy" cytoplasmic change. We present the case of a 59-year-old male who presented with progressive erythema and swelling of the midface and bilateral eyelids.
View Article and Find Full Text PDFResponse to: "Potential sitosterolemia in necrobiotic xanthogranuloma: Comment on Extensive yellowish masses in bilateral orbit and neck" by Chen et al.
J Dermatol
November 2024
Department of Rheumatology and Immunology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
Potential sitosterolemia in necrobiotic xanthogranuloma: Comment on "Extensive yellowish masses in bilateral orbit and neck".
J Dermatol
October 2024
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
The role of intravenous immunoglobulin in autoimmune diseases with dermatological implications.
Ital J Dermatol Venerol
October 2024
School of Medicine, Clinic of Dermatology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Article Synopsis
- Intravenous immunoglobulin (IVIG) therapy shows promise for treating various dermatological autoimmune diseases due to its ability to modulate the immune system and low risk of severe side effects.
- The exact mechanism of how IVIG works in autoimmune diseases is still debated, but it involves neutralizing harmful autoantibodies and preventing tissue damage.
- While IVIG is primarily used off-label for conditions like dermatomyositis and systemic sclerosis, a key study (ProDERM 2022) demonstrated its effectiveness specifically for dermatomyositis, and it is commonly used as first-line treatment for scleromyxedema.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!